| Etanercept in systemic juvenile idiopathic arthritis. | |
| | |
MedLine Citation:
|
PMID: 12412209 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the effectiveness of etanercept in patients with systemic juvenile idiopathic arthritis (SJIA) refractory to methotrexate (MTX) therapy in a pediatric rheumatology practice. METHODS: Fifteen patients with SJIA with active polyarthritis refractory to higher dose MTX (> or = 20 mg/m2/week) for at least 3 months were included. Patients received etanercept 0.4 mg/Kg twice weekly concomitantly with MTX. Observed period of treatment ranged from 5 to 12 months (median 9 months). RESULTS: Improvement of ESR, swollen and limited joint counts, functional capacity, and general wellbeing was achieved by 14/15 patients. The most significant impact on these variables was observed 3 to 5 months after treatment onset. Mean time to improvement was 2 months. In the 4 patients who presented fever and rash, these signs disappeared after the beginning of etanercept treatment and reappeared during flares. Three patients showed sustained clinical and biochemical remission on low dose MTX (< or = 5 mg/m2/week). Thirteen relapses were observed in 9 (60%) patients at a mean of 7.6 months after therapy was begun. Etanercept was discontinued due to lack of efficacy in 7 patients, only after higher dose (1 mg/kg/dose) was used. MTX and corticosteroid doses were decreased during the observation period. No serious side effects were observed. CONCLUSIONS: Etanercept, in combination with MTX, demonstrated benefit soon after initiation of treatment in patients with refractory SJIA, but flares and progressive loss of effectiveness were observed with continued treatment in most patients. Sharp decreases in the dose of MTX and corticosteroids may have contributed to subsequent occurrence of flares. Changes in MTX and corticosteroids doses should probably need to be made gradually, and it is possible that patients on SJIA should continue on therapeutic doses of MTX while being on etanercept in order to maintain therapeutic benefit. |
| | |
Authors:
|
R A G Russo; M M Katsicas; M Zelazko |
Related Documents
:
|
22928529 - A modified glasgow blatchford score improves risk stratification in upper gastrointesti... 8489539 - The effects of drug therapy on radiographic progression of rheumatoid arthritis. result... 23062969 - Outcomes of the infant ross procedure for congenital aortic stenosis followed into adol... 12734899 - Clinical and radiological changes during psoriatic arthritis disease progression. 19352339 - Comparison of two adalimumab treatment schedule strategies for moderate-to-severe crohn... 21255059 - Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in e... 23472309 - Tracheotomy tubes with suction above the cuff reduce the rate of ventilator-associated ... 19154899 - Health-related quality of life in esophageal cancer: effect of neoadjuvant chemoradioth... 9715049 - Functional outcome of double-stapled and transanal ileal pouch-anal anastomosis after p... |
Publication Detail:
|
Type: Evaluation Studies; Journal Article |
Journal Detail:
|
Title: Clinical and experimental rheumatology Volume: 20 ISSN: 0392-856X ISO Abbreviation: Clin. Exp. Rheumatol. Publication Date: 2002 Sep-Oct |
Date Detail:
|
Created Date: 2002-11-04 Completed Date: 2003-04-02 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8308521 Medline TA: Clin Exp Rheumatol Country: Italy |
Other Details:
|
Languages: eng Pagination: 723-6 Citation Subset: IM |
Affiliation:
|
Service of Immunology, Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Pichincha 1890, 1245 Buenos Aires, Argentina. rrusso@garrahan.gov.ar |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Antirheumatic Agents / therapeutic use* Arthritis, Juvenile Rheumatoid / drug therapy* Child Drug Administration Schedule Drug Therapy, Combination Female Humans Immunoglobulin G / therapeutic use* Male Methotrexate / therapeutic use Receptors, Tumor Necrosis Factor / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antirheumatic Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 185243-69-0/TNFR-Fc fusion protein; 59-05-2/Methotrexate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment of juvenile idiopathic arthritis with intra-articular triamcinolone hexacetonide: evaluati...
Next Document: A short-term follow-up of enthesitis and arthritis in the active phase of juvenile onset spondyloart...